Ethical committee approval is obtained from Ethics committee of Faculty of Medicine, Alexandria University.~All participants should agree to take part in this clinical study and will provide informed consent.~Patients with suspected H. pylori infection are recruited from Alexandria University out-patient clinics~Participants' demographic data, Full medical and medication history, and detailed clinical presentation is documented~Participants are tested for H. pylori infection using rapid H. pylori stool antigen test device~Negative subjects are excluded while positive patients are randomly allocated to 3 groups of different H. pylori regimens (Standard triple, Vonoprazan dual, and Vonoprazan triple)~Following up treatment side effects while taking the medications.~Assessing regimens effectiveness through patient retesting at least 1 month after treatment completion.~Assessing patient compliance to different regimens during the final visit.~Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results.~Results, conclusion, discussion and recommendations will be given.
Appropriately, half of the global population is infected with H. pylori, and it is now recognized that it causes at least 95% of all gastric cancers. Currently, the main challenge in the field of H. pylori infection is the rapidly increasing antibiotic resistance worldwide, which is causing a decline in the effectiveness of currently available eradication regimens.~The aim of the study is to assess the safety and efficacy of different H. pylori vonoprazan-based regimens compared to the commonly used standard triple therapy composed of Clarithromycin, Amoxicillin, and Proton pump inhibitor to eradicate H. pylori infection in treatment-naive patients through the determination of each regimen eradication rate and reported safety profile